Reportlinker Adds Lung Cancer Drug Futures
NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED
Espicom's Lung Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document.
24/7 web access
Quarterly updated pdf reports
Single cost-effective price
All updates including any new drugs added during your licence period
Espicom's research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.
Although a plethora of platinum-based chemotherapy combinations may be prescribed for the treatment of non small cell lung cancer (NSCLC)....
....the market is currently driven by chemotherapeutic agents such as taxanes and antimetabolites, and the increasing use of targeted therapies. Some of the newer chemotherapy agents such as Eli Lilly's Gemzar and Alimta have become the standard of care in combination with cisplatin or carboplatin and may be used in addition to or instead of the taxanes Taxotere or Taxol/generic paclitaxel.
The lung cancer market is set for radical change. A number of current first-line therapies will become subject to generic competition in the short term. Although chemotherapy will continue